BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect

被引:157
作者
Hallahan, AR
Pritchard, JI
Chandraratna, RAS
Ellenbogen, RG
Geyer, JR
Overland, RP
Strand, AD
Tapscott, SJ
Olson, JM [1 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA
[2] Univ Washington, Childrens Hosp, Div Pediat Oncol, Seattle, WA 98105 USA
[3] Allergan Pharmaceut Inc, Retinoid Res, Irvine, CA 92623 USA
[4] Univ Washington, Childrens Hosp, Dept Neurosurg, Seattle, WA 98105 USA
[5] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA
关键词
D O I
10.1038/nm904
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mechanisms of retinoid activity in tumors remain largely unknown. Here we establish that retinoids cause extensive apoptosis of medulloblastoma cells. In a xenograft model, retinoids largely abrogated tumor growth. Using receptor-specific retinoid agonists, we defined a subset of mRNAs that were induced by all active retinoids in retinoid-sensitive cell lines. We also identified bone morphogenetic protein-2 (BMP-2) as a candidate mediator of retinoid activity. BMP-2 protein induced medulloblastoma cell apoptosis, whereas the BMP-2 antagonist noggin blocked both retinoid and BMP-2-induced apoptosis. BMP-2 also induced p38 mitogen-activated protein kinase (MAPK), which is necessary for BMP-2- and retinoid-induced apoptosis. Retinoid-resistant medulloblastoma cells underwent apoptosis when treated with BMP-2 or when cultured with retinoid-sensitive medulloblastoma cells. Retinoid-induced expression of BMP-2 is thus necessary and sufficient for apoptosis of retinoid-responsive cells, and expression of BMP-2 by retinoid-sensitive cells is sufficient to induce apoptosis in surrounding retinoid-resistant cells.
引用
收藏
页码:1033 / 1038
页数:6
相关论文
共 50 条
[1]   The promise of retinoids to fight against cancer [J].
Altucci, L ;
Gronemeyer, H .
NATURE REVIEWS CANCER, 2001, 1 (03) :181-193
[2]   Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL [J].
Altucci, L ;
Rossin, A ;
Raffelsberger, W ;
Reitmair, A ;
Chomienne, C ;
Gronemeyer, H .
NATURE MEDICINE, 2001, 7 (06) :680-686
[3]   Medulloblastoma growth inhibition by Hedgehog pathway blockade [J].
Berman, DM ;
Karhadkar, SS ;
Hallahan, AR ;
Pritchard, JI ;
Eberhart, CG ;
Watkins, DN ;
Chen, JK ;
Cooper, MK ;
Taipale, J ;
Olson, JM ;
Beachy, PA .
SCIENCE, 2002, 297 (5586) :1559-1561
[4]  
Caricasole A, 2000, INT J DEV BIOL, V44, P443
[5]   A decade of molecular biology of retinoic acid receptors [J].
Chambon, P .
FASEB JOURNAL, 1996, 10 (09) :940-954
[6]   Tazarotene - First of a new generation of receptor-selective retinoids [J].
Chandraratna, RAS .
BRITISH JOURNAL OF DERMATOLOGY, 1996, 135 :18-25
[7]   Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice [J].
Conley, BA ;
Ramsland, TS ;
Sentz, DL ;
Wu, SL ;
Rosen, DM ;
Wollman, M ;
Eiseman, JL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 43 (03) :183-197
[8]   Histopathologic grading of medulloblastomas - A pediatric oncology group study [J].
Eberhart, CG ;
Kepner, JL ;
Goldthwaite, PT ;
Kun, LE ;
Duffner, PK ;
Friedman, HS ;
Strother, DR ;
Burger, PC .
CANCER, 2002, 94 (02) :552-560
[9]  
Evans AE, 1999, CLIN CANCER RES, V5, P3594
[10]  
Farah MH, 2000, DEVELOPMENT, V127, P693